With the in-depth research, increasing studies have revealed that not only IgG monoclonal antibodies but also non-IgG antibodies (IgA, IgM, and IgE) display pivotal effects and absolute advantages in human disease treatment, particularly tumor therapeutics. As an antibody service support company that is dedicated to human health, Creative Biolabs provides all-direction non-IgG therapeutic antibodies service started with non-IgG antibody production and purification.
Fig.1
Non-IgG antibodies production and purification.
Our Service
IgA Production and Purification
Quite different from IgG antibodies, IgA predominantly represents a dimeric form also called secretory IgA (sIgA) that distributes in mucous secretions, while monomeric IgA exists in serum with a small number. Based on its properties, IgA production by classical hybridomas technology tends to immunize animals through the mucosal presentation of antigens, which can increase the frequency of IgA-producing B cells in the spleen. The main solution we chose for IgA generation is recombinant technology based on our Expression System Platform. IgA purification can be conducted by chromatography including affinity chromatography (protein A/G/L and peptide M) and exchange chromatography.
IgM Production and Purification
Production of IgM antibodies in quantities is more difficult than IgG antibodies due to their large molecule weight and polymeric form. Currently, IgM antibodies can be produced by hybridoma technique and recombinant technology. Size exclusion chromatography and ion-exchange chromatography, rather than affinity chromatography (including protein A/G), are more suitable for IgM purification.
IgE Production and Purification
IgE antibody is the least abundant isotype that only exists in mammals, which plays a significant role in anti-parasitic infection, allergic reactions, and anti-tumor effects. For further anti-tumor treatment research, we produce recombinant IgE antibodies by single-cell amplification based on our well-established expression system platform and then purify IgE antibodies by suitable affinity chromatography.
IgY Production and Purification
Compared with mammalian IgG antibodies, the high specificity, high affinity, and lower risk of cross-reactivity endow IgY antibodies with application value in the field of laboratory research and diagnosis. Creative Biolabs also has developed s seasoned approach for IgY antibody production and purification in a cost-saving manner.
Advanced Platform
Creative Biolabs has established a state-of-the-art Antibody Expression System Platform designed to accommodate the production of various antibody isotypes, including IgG, IgA, IgM, and IgE. Our platform features an extensive selection of stable cell lines, such as CHO cells, NS0, SP2/0, YB2/0 myeloma cells, baby hamster kidney cells, COS cells, insect cells, and PER.C6 human cell lines. For specialized needs, we offer human glyco-engineered cell systems to ensure optimized glycosylation, enhancing immunogenicity, bioactivity, and half-life. With our advanced cell lines and customizable solutions, Creative Biolabs provides unparalleled quality and scalability for antibody expression tailored to research, diagnostic, and therapeutic applications.
Follow the pace of industry leaders and accelerate your research progress with tailored solutions and detailed data reports.
Get Your Quate NowQuotation and Ordering
Our customer service representatives are available 24/7/365. You may contact us anytime for assistance. Orders can be placed online, over the phone, by email, or by fax.
Service Advantages
- Extensive Expertise in Non-IgG Antibodies - Creative Biolabs specializes in producing and purifying complex non-IgG antibodies, including IgA, IgM, IgE, and IgY, leveraging years of experience and cutting-edge techniques.
- Advanced Expression System Platform - Our robust expression systems ensure high-yield production of non-IgG antibodies, tailored to the unique requirements of each antibody isotype for optimal performance.
- Customized Experimental Design - Fully customizable workflows allow us to go beyond standard procedures, adapting to specific research goals and ensuring precise outcomes for every project.
- Innovative Purification Techniques - Utilizing techniques such as size exclusion chromatography, ion-exchange chromatography, and specialized affinity chromatography, we ensure high purity and functionality of non-IgG antibodies.
- Solutions for Complex Antibody Structures - Addressing the unique challenges of non-IgG antibodies, such as IgA's dimeric form and IgM's polymeric structure, we employ specialized strategies to maintain structural integrity and activity.
- Comprehensive Coverage of Antibody Isotypes - From monomeric or dimeric IgA to multimeric IgM and avian IgY, our service encompasses a wide range of antibody types, supporting diverse applications in research, diagnostics, and therapeutics.
- High Purity and Specificity - Each antibody is produced and purified to meet stringent quality standards, with purity levels exceeding 95% and excellent specificity for its intended target.
- Cost-effective and Scalable Solutions - Our service combines affordability with scalability, catering to projects of varying sizes while ensuring consistent quality for both small and large-scale production.
FAQs
Q1: What challenges are associated with non-IgG antibody production, and how are they overcome?
A: Non-IgG antibodies pose challenges due to their size, structural complexity, and glycosylation. These challenges are addressed using advanced expression systems, optimized purification methods, and specialized expertise in handling isotype-specific requirements.
Q2: What are the key applications for non-IgG antibodies produced through this service?
A: Our non-IgG antibodies are widely used in tumor therapeutics, anti-parasitic studies, allergic reaction research, and diagnostic development, among other fields.
Q3: Can the service be customized for specific research needs?
A: Yes, we offer fully customizable workflows, including experimental design, expression conditions, and purification strategies, to meet unique project requirements.
Q4: Can antibodies be produced in large quantities for preclinical studies?
A: Yes, scalable expression systems are available to produce non-IgG antibodies in quantities suitable for both small-scale research and large-scale preclinical studies.
Q5: What support does Creative Biolabs provide during the project?
A: Our Ph.D.-level scientists and professional staff provide end-to-end technical support, from initial planning to final product delivery, ensuring the success of each project.
Q6: How long does it typically take to produce and purify non-IgG antibodies?
A: The timeline depends on the complexity of the project and the antibody isotype, but efficient workflows ensure delivery within a reasonable timeframe, aligned with research needs.
Resource
Click the Video to Learn More about Non-IgG Antibody
KINDLY NOTE
!! For Research Use Only. Our products and services are NOT intended for diagnostic or therapeutic applications.
